The Role of Systemic Treatments in Vitiligo
Support for various systemic treatments for vitiligo is reviewed.
Vitiligo
Evidence Lacking for Tocilizumab Use in Dermatologic Conditions
The clinical dermatologic use of tocilizumab, its mechanisms of action, and adverse events is reviewed.
Vitiligo: Current Understanding and Future Treatment Directions
Current knowledge about vitiligo and potential treatments are reviewed.
Antioxidant Adjuvant Therapy for Improved Vitiligo Outcomes
The efficacy of gliadin-protected to superoxide dismutase (SOD) in conjunction with phototherapy for addressing vitiligo was assessed.
Risk for Autoimmunity Up With Concomitant Vitiligo, Psoriasis
Individuals with co-occurrence of vitiligo and psoriasis have an increased risk for autoimmunity and family history of psoriasis.
Repigmentation Observed With Ruxolitinib Cream in Vitiligo Trials
Results from both studies demonstrated that ruxolitinib met the primary endpoint with a greater proportion of patients achieving F-VASI75 at week 24.
Ruxolitinib Cream a Promising Option for Long-Term Vitiligo Treatment
The safety and efficacy of ruxolitinib cream following 104 weeks of treatment in a phase 2 study of adults is reported.
Do Patients With Vitiligo Have Higher Risk for Metabolic Disturbances?
The prevalence and association of metabolic syndrome in patients with vitiligo was determined via analyses in this study.
Vitiligo: Present and Future, With John E. Harris, MD
Expert on vitiligo John E. Harris, MD, associate professor of dermatology at University of Massachusetts Medical School (UMMS) in Worcester, spoke with us about the skin disorder.
Platelet-Rich Plasma Added to MPG/Phototherapy May Lead to Earlier Repigmentation Response
Treatment outcomes for the mini punch grafting/phototherapy treatment with and without PRP were assessed in patients with vitiligo.
- Loading...
Loading...
Next post in General Dermatology
Loading... 
Loading...